期刊文献+

耐药相关基因拓扑异构酶-Ⅱα在人胰腺癌细胞株中的表达 被引量:2

Expression of Drug Resistant Associated Gene TOPO-Ⅱαin Human Pancreatic Cancer Cell Lines.
下载PDF
导出
摘要 目的:探讨耐药相关基因拓扑异构酶鄄Ⅱα((TOPO鄄Ⅱα)在人胰腺癌细胞株中的表达。方法:通过逆转录鄄聚合酶链反应(RT鄄PCR)和Western鄄blot方法测定6株人胰腺癌细胞株(SW1990、Capan鄄2、AsPC鄄1、MiAPaCa鄄2、PANC鄄1、P3)中的TOPO鄄Ⅱα在基因和蛋白水平上的表达。结果:①TOPO鄄Ⅱα基因的表达以SW1990最高,PANC鄄1最低,与其他细胞株相比均具有显著性差异(P<0.05);②TOPO鄄Ⅱα蛋白的表达以SW1990、Capan鄄2较高,AsPC鄄1较低。SW1990,Capan鄄2与其余4株之间存在着显著性差异(P<0.05),而SW1990与Capan鄄2之间无显著性差异(P>0.05);AsPC鄄1、MiAPaCa鄄2、PANC鄄1、P3之间均无显著性差异(P>0.05)。结论:胰腺癌细胞对TOPO鄄Ⅱα抑制剂的低敏感性与TOPO鄄Ⅱα蛋白的低水平表达有关,TOPO鄄Ⅱα可能参与了胰腺癌对化疗的耐药。 Objective:To investigate the expression of TOPOⅡαin six Human pancreatic cancer cell lines(SW1990,Capan2,AsPC1,MiAPaCa2,PANC1,P3)as well as the relationship between TOPOⅡαand drug resistance in pancreatic cancer.Methods:The expression of TOPOⅡαon genetic level was determined by semiquantitative RTPCR.The expression of TOPOⅡαon protein level was determined by Western blot.Results:SW1990had the highest level of TOPOⅡαgene expression,PANC1had the lowest level of expression;there was significant difference between SW1990and PANC1compared to the other four cell lines.Capan2and SW1990had the relative higher levels of TOPOⅡαprotein expression,and AsPC1had the lowest.There was significant difference between Capan2,SW1990and the other four cell lines(P<0.05);there was no significant difference between Capan2and SW1990(P>0.05),there was also no significant difference among the other four cell lines(P>0.05).Conclusions:All showed that six cell lines with different expression levels in gene and protein of TOPOⅡα.Considering results of our previous studies,the low sensitivity of pancreatic cancer cells to inhibitors of TOPOⅡαwas related with low expression of TOPOⅡαand has a relationship with multidrug resistance in pancreatic cancer.
机构地区 中国医学科学院
出处 《外科理论与实践》 2003年第1期65-67,共3页 Journal of Surgery Concepts & Practice
基金 国家教委优秀青年教师基金 中国医学科学院北京协和医院重点科研项目基金资助。
关键词 耐药相关基因 拓扑异构酶-Ⅱα 胰腺癌 细胞株 多药耐药 Pancreatic cancer Topoisomerase-Ⅱ(TOPO-Ⅱα)Multidrug resistance
  • 相关文献

参考文献2

二级参考文献12

  • 1Schneider E,Hsiang YH,Liu LF.DNAtopoisomerases as anticancer drug targets[J].Adv Pharmacol,1990,21:149~183.
  • 2Katoh R,Bray CE,Suzuki K,et al.Growth activity in hyperplastic and neoplastic humanthyroid determined by an immunohistochemical staining procedure using monoclonal antibodyMIB-1[J].Hum Pathol,1995,26:139~146.
  • 3Drake FH,Hofmann GA,Bartus HF,et al.Biochemical and pharmacological properties ofp170 and p180 forms of topoisomerase Ⅱ[J].Biochemistry,1989,28:8154~8160.
  • 4Fry AM,Chresta CM,Davies SM,et al.Relationship between topoisomerase Ⅱ level andchemosensitivity in human tumor cell lines[J].Cancer Res,1991,51:6592~6595.
  • 5Uemura T,Ohkura H,Adachi Y,et al.DNA topoisomerase Ⅱ is required for condensationand separation of mitotic chromosomes in S.Pombe[J].Cell,1987,50:917~925.
  • 6Kaufmann SH,McLaughlin SJ,Kastan MB,et al.Topoisomerase Ⅱ levels duringgranulocytic maturation in vitro and in vivo[J].Cancer Res,1991,51:3534~3543.
  • 7Kasahara K,Fujiwara Y,Sugimoto Y,et al.Determinants of response to the DNAtopoisomerase Ⅱ inhibitors doxorubicin and etoposide in human lung cancer lines[J].JNatl Cancer Inst,1992,84:113~118.
  • 8Nitiss JL,Liu YX,Harbury P,et al.Amsacrine and etoposide hypersentivity of yeastcells overexpressing DNA topoisomerase Ⅱ[J].Cancer Res,1992,52:4467~4472.
  • 9Oya M,Yao T,Nagai F,et al.Metastasizing intramucosal gastric carcinomas:welldifferentiated type and proliferative activity using proliferative cell nuclear antigenand ki-67[J].Cancer,1995,75:926~935.
  • 10Schluter C,Duchrow M,Wohlenberg C,et al.The cell proliferation-associated antigenof antibody ki-67: a very large,ubiquitous nuclear protein with numerous repeatedelements,representing a new kind of cell cycle-maintaining proteins[J].J CellBiol,1993,123:513~522.

共引文献6

同被引文献21

  • 1陈革,赵玉沛,郭俊超,张立阳,李丽君,吴元德.胰腺癌细胞株耐药与凋亡相关基因的改变[J].外科理论与实践,2004,9(4):325-328. 被引量:3
  • 2潘博,郭俊超,廖泉,赵玉沛.吉西他滨与胰腺癌化疗耐药[J].中国普外基础与临床杂志,2005,12(5):530-532. 被引量:16
  • 3郭俊超,赵玉沛,廖泉,陈革,张立阳.胰腺癌耐药细胞株SW1990/FU的建立、鉴定及生物学特性[J].中国医学科学院学报,2005,27(5):592-596. 被引量:15
  • 4Jemal A, Thomas A, Murray T, et al. Cancer Statistics,2002. CA Cancer J Clin, 2002, 52(1):23-47.
  • 5Kyriazis AP, McCombs WB, Sandberg AA, et al. Establishment and characterization of human pancreatic adenocarcinoma cell strain SW1990 in tissue culture and the nude mouse. Cancer Res, 1983, 43(9):4393-4401.
  • 6Nitta A, Chung YS, Nakata B, et al. Establishment of a cisplatin-resistant gastric carcinoma cell line OCUM-2M/DDP. Cancer Chemother Pharmacol, 1997, 40(1):94-97.
  • 7Kayed H, Kleeff J, Keleg S, et al. Indian hedgehog signaling pathway: expression and regulation in pancreatic cancer. Int J Cancer, 2004, 110(5):668-676.
  • 8Li J, Kleeff J, Guo J, et al. Effects of STI571 (gleevec)on pancreatic cancer cell growth. Mol Cancer, 2003, 2(1):32.
  • 9Lefter LP, Sunamura M, Furukawa T, et al. Functional analysis of chromosome 18 in pancreatic cancer: strong evidence for new tumour suppressor genes. Asian J Surg,2004, 27(2):85-92.
  • 10Kawano K, Iwamura T, Yamanari H, et al. Establishment and characterization of a novel human pancreatic cancer cell line (SUIT-4) metastasizing to lymph nodes and lungs in nude mice. Oncology, 2004, 66(6):458-467.

引证文献2

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部